Once a drug developer has identified a viable molecule, one of the more complex decisions that must be made is defining the process used to produce, harvest, and purify said molecule. There is a need for innovative single-use technology to support the monoclonal antibody (mAb), recombinant protein, bioengineered vaccine, gene therapy, and cell therapeutic segments, accommodating the market growth forecast in the coming years. With a growing need for optimization of processes requiring high cell densities and more efficient workflow steps to alleviate bioproduction bottlenecks, customers are seeking robust innovations in the harvest step to address unmet needs they are facing. More specifically, those needs often revolve around finding ways to drive down operational costs while still managing to develop a process that is sustainable.

Complete this form to download a thought leadership article that covers sustainability, time, cost, space, and scale with harvest solutions.